PMID- 35696794
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 22
DP  - 2022 Aug
TI  - Effects of USP7 on radiation sensitivity through p53 pathway in laryngeal 
      squamous cell carcinoma.
PG  - 101466
LID - S1936-5233(22)00125-5 [pii]
LID - 10.1016/j.tranon.2022.101466 [doi]
LID - 101466
AB  - The relationship between ubiquitin specific protease 7 (USP7) and 
      radio-sensitivity in laryngeal squamous cell carcinoma (LSCC) has not been 
      reported yet. Using gene chip and Label-Free mass spectrometry, we found that 
      USP7 was significantly increased both in radioresistant LSCC patients and LSCC 
      cells receiving irradiation. Since p53 is the most important downstream gene of 
      USP7 and is frequently mutated in LSCC, we investigated the effects of USP7 on 
      radioresistance of LSCC cells with or without p53 mutation. We found that 
      knockdown of USP7 increased the radio-sensitivity in p53-mutated LSCC cells, 
      while inhibiting the radio-sensitivity in p53-wild type cells. Knockdown of USP7 
      significantly inhibited the expression of the p53 and p53 pathway. Overexpressing 
      endogenous p53 by CRISPR/dCas9 could reverse the effects of USP7 on 
      radiosensitivity both in vitro and in vivo. Our results demonstrated the 
      irradiation-induced USP7 led to radioresistance in p53-mutated LSCC cells but 
      radio-sensitivity in p53-wild type cells. Therefore, the clinical application of 
      USP7 inhibitors may improve the effects of radiotherapy in LSCC with p53 
      mutations and reduce the side effects on surrounding normal tissues without p53 
      mutation.
CI  - Copyright (c) 2022. Published by Elsevier Inc.
FAU - Niu, Hao
AU  - Niu H
AD  - Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, 
      China; Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of 
      Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, 
      Shanghai, China.
FAU - Zhu, Yi
AU  - Zhu Y
AD  - Department of Radiation Oncology, Eye and ENT Hospital, Fudan University, 
      Shanghai, China.
FAU - Wang, Jie
AU  - Wang J
AD  - Department of Radiation Oncology, Eye and ENT Hospital, Fudan University, 
      Shanghai, China.
FAU - Wang, Tian
AU  - Wang T
AD  - Department of Radiation Oncology, Eye and ENT Hospital, Fudan University, 
      Shanghai, China.
FAU - Wang, Xiaosheng
AU  - Wang X
AD  - Department of Radiation Oncology, Eye and ENT Hospital, Fudan University, 
      Shanghai, China. Electronic address: xiaosheng.wang@fdeent.org.
FAU - Yan, Li
AU  - Yan L
AD  - Department of Radiation Oncology, Eye and ENT Hospital, Fudan University, 
      Shanghai, China. Electronic address: yanl13@fudan.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220610
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC9194850
OTO - NOTNLM
OT  - Cancer genetic
OT  - Head and neck cancer
OT  - Laryngeal
OT  - Radiotherapy
COIS- None.
EDAT- 2022/06/14 06:00
MHDA- 2022/06/14 06:01
PMCR- 2022/06/10
CRDT- 2022/06/13 18:16
PHST- 2022/04/06 00:00 [received]
PHST- 2022/05/29 00:00 [revised]
PHST- 2022/06/05 00:00 [accepted]
PHST- 2022/06/14 06:00 [pubmed]
PHST- 2022/06/14 06:01 [medline]
PHST- 2022/06/13 18:16 [entrez]
PHST- 2022/06/10 00:00 [pmc-release]
AID - S1936-5233(22)00125-5 [pii]
AID - 101466 [pii]
AID - 10.1016/j.tranon.2022.101466 [doi]
PST - ppublish
SO  - Transl Oncol. 2022 Aug;22:101466. doi: 10.1016/j.tranon.2022.101466. Epub 2022 
      Jun 10.